These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 461989)

  • 1. Evaluation of various isoniazid slow releasing matrix preparations for intermittent chemotherapy of tuberculosis.
    Hodgkin MM; Eidus L; Hershfield ES
    Res Commun Chem Pathol Pharmacol; 1979 May; 24(2):349-65. PubMed ID: 461989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the acetylator phenotype using matrix isoniazid.
    Ellard GA; Gammon PT; Titinen H
    Tubercle; 1975 Sep; 56(3):203-9. PubMed ID: 1216339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic studies with an isoniazid slow-releasing matrix preparation.
    Eidus L; Hodgkin MM; Hsu AH; Schaefer O
    Am Rev Respir Dis; 1974 Jul; 110(1):34-42. PubMed ID: 4834616
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative blood levels and metabolism of INH and an INH-matrix preparation in fast and slow inactivators.
    Jeanes CW; Schaefer O; Eidus L
    Can Med Assoc J; 1973 Sep; 109(6):483-7. PubMed ID: 4742916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoniazid levels in black patients dosed with a matrix preparation (Tebesium).
    Glatthaar E; Gärtig D; Stander MF; Kleeberg HH
    Prax Klin Pneumol; 1977 Oct; 31(10):855-9. PubMed ID: 928288
    [No Abstract]   [Full Text] [Related]  

  • 6. [Type of isoniazid (INH) acetylation determined in tuberculosis patients treated at the Institute of Tuberculosis and Lung Diseases in Warsaw during the years 1990-1997].
    Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2002; 70(3-4):180-92. PubMed ID: 12271965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further studies on the pharmacology of a slow-release matrix preparation of isoniazid (Smith and Nephew HS 82) of potential use in the intermittent treatment of tuberculosis.
    Ellard GA; Gammon PT; Polansky F; Víznerová A; Havlík I; Fox W
    Tubercle; 1973 Mar; 54(1):57-66. PubMed ID: 4774935
    [No Abstract]   [Full Text] [Related]  

  • 8. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.
    Zabost A; Brzezińska S; Kozińska M; Błachnio M; Jagodziński J; Zwolska Z; Augustynowicz-Kopeć E
    Biomed Res Int; 2013; 2013():853602. PubMed ID: 24383060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.
    Donald PR; Parkin DP; Seifart HI; Schaaf HS; van Helden PD; Werely CJ; Sirgel FA; Venter A; Maritz JS
    Eur J Clin Pharmacol; 2007 Jul; 63(7):633-9. PubMed ID: 17505821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe.
    Aït Moussa L; Khassouani CE; Hüe B; Jana M; Bégaud B; Soulaymani R
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):548-53. PubMed ID: 12503812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid acetylator status of Black South African tuberculosis patients.
    Bach PH; Higgins-Opitz SB; Bima B; Leary WP
    S Afr Med J; 1976 Jul; 50(29):1132-4. PubMed ID: 959925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.
    Ellard GA
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 2):610-25. PubMed ID: 773583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new isoniazid preparation designed for moderately fast and "fast" metabolizers of the drug.
    Eidus L; Hodgkin MM
    Arzneimittelforschung; 1975 Jul; 25(7):1077-80. PubMed ID: 1101901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acetylation phenotype of isoniazid in Morocco. Preliminary study of 100 cases].
    Bouayad Z; Chevalier B; Maurin R; Bartal M
    Rev Fr Mal Respir; 1982; 10(6):401-7. PubMed ID: 7163595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained release isoniazid tablets. I--Formulation and in vitro evaluation.
    Bulut-Oner F; Capan Y; Kas S; Oner L; Hincal AA
    Farmaco; 1989; 44(7-8):739-52. PubMed ID: 2590371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of acetyl hydrazines and rate of acetylation of isoniazid in adult tuberculosis patients.
    Bhalerao EB; Bhide SV
    Indian J Physiol Pharmacol; 1985; 29(2):83-8. PubMed ID: 4093196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotyping of South African black tuberculosis patients for inactivation of isoniazid.
    Eidus L; Glatthaar E; Hodgkin MM; Nel EE; Kleeberg HH
    Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):243-56. PubMed ID: 461951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis.
    Nagel S; Streicher EM; Klopper M; Warren RM; Van Helden PD
    Curr Drug Metab; 2017; 18(11):1030-1039. PubMed ID: 29086682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
    Jing W; Zong Z; Tang B; Wang J; Zhang T; Wen S; Xue Y; Chu N; Zhao W; Huang H
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.
    Donald PR; Sirgel FA; Botha FJ; Seifart HI; Parkin DP; Vandenplas ML; Van de Wal BW; Maritz JS; Mitchison DA
    Am J Respir Crit Care Med; 1997 Sep; 156(3 Pt 1):895-900. PubMed ID: 9310010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.